Abstract
Dara Lehman and colleagues discuss a randomized trial that found that adding up to a week of twice-daily zidovudine+lamivudine to single-dose nevirapine reduces the risk of resistance in mothers and infants.
MeSH terms
-
Anti-HIV Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active
-
Drug Resistance, Viral*
-
Female
-
HIV Infections / prevention & control*
-
HIV Infections / transmission
-
HIV-1 / drug effects*
-
Humans
-
Infectious Disease Transmission, Vertical / prevention & control*
-
Lamivudine / therapeutic use
-
Nevirapine / therapeutic use
-
Pregnancy
-
Pregnancy Complications, Infectious / prevention & control*
-
Pregnancy Complications, Infectious / virology
-
Zidovudine / therapeutic use
Substances
-
Anti-HIV Agents
-
Lamivudine
-
Zidovudine
-
Nevirapine